Nabriva Therapeutics announced topline results from their Phase 1 clinical trial that assessed the safety and pharmacokinetics of oral and intravenous XENLETA in adult patients with cystic fibrosis. "We are excited to share positive topline results from this important study of XENLETA in patients with CF," said Christine Guico-Pabia, M.D., MBA, MPH, Nabriva’s Chief Medical Officer. "The data indicate that the PK of XENLETA in CF patients is consistent with that observed in previous single-dose healthy volunteer studies evaluating the approved oral and IV dosing for adults with community-acquired bacterial pneumonia . In addition, XENLETA was well-tolerated and the adverse event profile in CF patients was consistent with that described across our clinical program. XENLETA has been demonstrated to be a potent anti-staphylococcal antibiotic in in vitro and clinical studies, including against methicillin-resistant S. aureus. There are limited treatment options for the management of bacterial exacerbations in CF patients caused by S. aureus and the results of this study support the potential utility of XENLETA in this difficult to treat patient population. We would like to thank the study participants, investigators, and the Cystic Fibrosis Foundation for their support of this important study and look forward to sharing the complete results with the medical community in the first half of 2023."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on NBRV:
